文献速递肝病

NAFLD患者CAP的M与XL探头同日直接比较:以MRI-PDFF为标准

Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-12-13

这项前瞻性研究纳入100名成人(平均BMI 30.6±4.7 kg/m²),同日使用M探头和XL探头测量CAP,并以MRI-PDFF为标准。结果显示M探头测得的CAP值显著低于XL探头,且该差异独立于BMI。解读NAFLD患者的CAP数据时应考虑探头类型。

要点

  • M探头诊断MRI-PDFF≥5%和≥10%的最佳阈值分别为294 dB/m和311 dB/m。
  • XL探头诊断MRI-PDFF≥5%和≥10%的最佳阈值分别为307 dB/m和322 dB/m。

核心结论

  • M探头相比XL探头会低估CAP值,且该差异独立于BMI。
  • 解读NAFLD患者的CAP数据时应考虑所用探头类型。

研究设计与样本

  • 前瞻性研究,纳入100名成人(平均BMI 30.6±4.7 kg/m²),于2017年11月至2018年11月在单中心同日使用M探头和XL探头测量CAP。
  • 以MRI-PDFF为参考标准,定义肝脂肪变为MRI-PDFF≥5%,肝脂肪含量≥10%为MRI-PDFF≥10%。

主要发现

  • 68%的参与者MRI-PDFF≥5%,48%的参与者MRI-PDFF≥10%。

关键数值与推荐

  • M探头诊断MRI-PDFF≥5%的最佳CAP阈值为294 dB/m,诊断MRI-PDFF≥10%的最佳阈值为311 dB/m。
  • XL探头诊断MRI-PDFF≥5%的最佳CAP阈值为307 dB/m,诊断MRI-PDFF≥10%的最佳阈值为322 dB/m。

临床怎么用

  • 临床解读NAFLD患者的CAP结果时需明确探头类型,避免因探头不同导致误判。
  • 可参考本研究提供的M和XL探头对应MRI-PDFF≥5%及≥10%的最佳阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Controlled attenuation parameter (CAP) measurements using M probe have been reported to be lower than those of the XL-probe in detection of hepatic steatosis. However, there has been no direct comparison of CAP with the M vs the XL probe in patients with nonalcoholic fatty liver disease (NAFLD). We compared CAP with the M vs the XL probe for quantification of hepatic fat content, using magnetic resonance imaging proton density fat fraction (MRI-PDFF) as the standard. METHODS: We performed a prospective study of 100 adults (mean body mass index [BMI], 30.6 ± 4.7 kg/m2) with and without NAFLD, assessed by CAP with the M probe and XL probe on the same day, at a single research center, from November 2017 through November 2018. We then measured the MRI-PDFF as the reference standard. Outcomes were presence of hepatic steatosis, defined as MRI-PDFF ≥ 5%, and detection of hepatic fat content ≥ 10%, defined as MRI-PDFF ≥ 10%. We performed area under the receiver operating characteristic curve (AUROC) analyses to assess the diagnostic accuracy of CAP for each probe in detection of hepatic steatosis (MRI-PDFF ≥ 5%) and of hepatic fat content ≥ 10%. RESULTS: Of the study participants, 68% had an MRI-PDFF of 5% or more and 48% had an MRI-PDFF of 10% or more. The mean CAP measured by the M probe (310 ± 62 db/m) was significantly lower than by the X probe (317 ± 63 db/m) (P = .007). When M probe was used in participants with BMIs <30 kg/m2 and XL probe in participants with BMIs ≥30 kg/m2, the CAP measured by the M probe (312 ± 51.4 db/m) remained significantly lower than that of the XL probe (345 ± 47.6 db/m) (P = .0035.), when the MRI-PDFF was above 5%. The optimal threshold of CAP for the detection of MRI-PDFF≥5%, was 294 db/m with the M probe and 307 db/m with the XL probe. The optimal threshold of CAP for the detection of MRI-PDFF ≥ 10%, was 311 db/m with the M probe and 322 db/m with the XL probe. For only the XL probe, CAP measurements with an interquartile range below 30 dB/m detected an MRI-PDFF≥5% with a lower AUROC (0.97; 95% CI, 0.80-1.00) than CAP measurements with an interquartile range above 30 dB/m (AUROC, 0.82; 95% CI, 0.71-0.90) (P = .0129). CONCLUSIONS: In an analysis of the same patients using CAP with the M probe and XL probe, with MRI-PDFF as the standard, we found that the M probe under-quantifies CAP values compared with the XL probe, independent of BMI. The type of probe should be considered when interpreting CAP data from patients with NAFLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Caussy C, Brissot J, Singh S, et al. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard. Clin Gastroenterol Hepatol. 2019. PMID: 31843596. doi:10.1016/j.cgh.2019.11.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。